Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

cybin deal

Finance

11 Dec 2023

Tryp Therapeutics To Be Acquired by Exopharm

Tryp Therapeutics announces signing of definitive agreement with Exopharm Limited....

By Microdose NewsDesk
patent

Industry

6 Dec 2023

Cybin Granted U.S. Patent For CYB003 Psilocybin Program

New patent provides IP protection until at least 2041. Cybin’s patent portfolio now includes 39 granted patents and over 170 pending applications....

By Microdose NewsDesk

Don’t Miss

4 Dec 2023

News You Might Have Missed: Dec 4th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed...

By Microdose NewsDesk

Breaking News

30 Nov 2023

Cybin Reports Positive Topline Data from Phase 2 Study of Major Depressive Disorder

Potentially groundbreaking results as Cybin's Phase 2 Study of CYB003 in Major Depressive Disorder showed 79% of patients in remission after two 12mg doses....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Science

27 Nov 2023

New Study Looks at Shame, Guilt and the Psychedelic Experience

A new study looks at emotionally painful, shame-related processes with psychedelic use....

By Microdose NewsDesk

Finance

24 Nov 2023

Filament Health Announces US$14.4 million Funding & Planned NASDAQ Listing

Filament Health has signed a non-binding term sheet for up to US$14.4 million in funding through a convertible note....

By Microdose NewsDesk
news psychedelic

Don’t Miss

20 Nov 2023

News You Might Have Missed: Nov 20th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed...

By Microdose NewsDesk

Breaking News

26 Oct 2023

Breaking News: Beckley Waves Acquires Nue Life

In breaking news, Beckley Waves announces the acquisition of Nue Life....

By Microdose NewsDesk
DMT

Uncategorized

25 Oct 2023

Cybin Granted Two New Patents For DMT Program

Cybin has added to this growing IP portfolio with the granting of two more patents for its DMT program....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.